Product image of Nintedanib Newbury (Nintedanib) supplied by GNH India

Nintedanib Newbury

Active Ingredient:
Nintedanib
Origin:
EU

Nintedanib Newbury (Nintedanib)

Nintedanib, the active ingredient in Nintedanib Newbury, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It treats idiopathic pulmonary fibrosis, systemic sclerosis‑associated interstitial lung disease, and non‑small cell lung cancer in appropriate patients.

GNH India supplies Nintedanib Newbury as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Newbury Pharmaceuticals Ab

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Nintedanib is used to target fibrotic and neoplastic processes in several lung‑related conditions.

  • Idiopathic pulmonary fibrosis: slows decline in lung function and reduces disease progression.
  • Systemic sclerosis‑associated interstitial lung disease: helps preserve lung capacity and delay worsening.
  • Non‑small cell lung cancer: used in combination therapy to inhibit tumor growth and angiogenesis.

How It Works

  • Nintedanib blocks multiple receptor tyrosine kinases, notably VEGFR 1‑3, FGFR 1‑3 and PDGFR‑α/β. By inhibiting these pathways it reduces fibroblast proliferation, angiogenesis and extracellular‑matrix deposition, thereby limiting both fibrotic tissue formation and tumor vascularisation.

Side Effects

Nintedanib may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Diarrhea: frequent loose stools.
  • Nausea: feeling sick.
  • Decreased appetite: reduced desire to eat.
  • Abdominal pain: stomach discomfort.

Serious or Rare Side Effects

  • Liver enzyme elevation: increased ALT/AST.
  • Bleeding events: gastrointestinal hemorrhage.
  • Interstitial lung disease worsening: rapid respiratory decline.

Precautions & Warnings

When prescribing Nintedanib, clinicians should consider several safety measures.

  • Monitor liver function: perform baseline and periodic ALT/AST tests.
  • Assess bleeding risk: avoid concomitant anticoagulants if possible.
  • Evaluate cardiovascular status: watch for hypertension or thrombotic events.
  • Pregnancy and lactation: use only if benefits outweigh risks; limited data.
  • Renal impairment: adjust monitoring in severe kidney disease.
  • Store at ambient temperature: keep below 25°C in original packaging, protect from moisture.

Avoid Interactions

Nintedanib can interact with other medicines; some combinations should be avoided while others require close monitoring.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase nintedanib exposure.
  • Anticoagulants (e.g., warfarin): heightened bleeding risk.
  • Antiplatelet agents (e.g., aspirin, clopidogrel): increased hemorrhage potential.

Moderate Interactions (Monitor Closely)

  • Moderate CYP3A4 inhibitors (e.g., erythromycin): may modestly raise levels.
  • P‑glycoprotein inhibitors (e.g., verapamil): could affect drug transport.
  • CYP3A4 inducers (e.g., rifampicin): may reduce efficacy.

Frequently Asked Questions

Nintedanib Newbury is prescribed for three main indications: idiopathic pulmonary fibrosis (IPF), systemic sclerosis‑associated interstitial lung disease (SSc‑ILD), and non‑small cell lung cancer (NSCLC). In each case the drug works to slow disease progression by targeting pathways that drive fibrosis or tumor growth.

Nintedanib inhibits several receptor tyrosine kinases—VEGFR, FGFR and PDGFR. Blocking these receptors reduces fibroblast proliferation, angiogenesis and extracellular‑matrix formation, which together limit fibrotic tissue development and the formation of new blood vessels that support tumor growth.

The dosing regimen for Nintedanib Newbury is determined by the prescribing clinician based on the specific indication, patient characteristics and any concomitant therapies. Healthcare professionals should follow the approved prescribing information and adjust the dose only as directed.

Safety data for Nintedanib during pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies the potential risk to the fetus or infant, and it is generally avoided unless no suitable alternatives exist.

To request Nintedanib Newbury, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative for IPF is pirfenidone, another antifibrotic agent. While both slow disease progression, Nintedanib targets a broader range of tyrosine kinases, which can also be advantageous in certain cancer settings. Choice of therapy depends on patient tolerance, comorbidities and physician judgment.

Nintedanib Newbury should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product away from moisture and direct sunlight to maintain stability throughout its shelf life.

Nintedanib Newbury is taken orally as a tablet with a full glass of water. It can be taken with or without food, but patients should follow the specific instructions provided by their healthcare professional.

Serious adverse events include significant liver enzyme elevations, bleeding complications (especially gastrointestinal), and rapid worsening of underlying lung disease. Patients should be educated to report signs such as jaundice, unusual bruising, severe abdominal pain or sudden breathlessness.

Nintedanib is contraindicated in patients with known hypersensitivity to the active substance or any excipients. Caution is advised for individuals with severe hepatic impairment, uncontrolled bleeding disorders, or those taking strong CYP3A4 inhibitors without appropriate medical supervision.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Nintedanib

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT